梅斯作为媒体参加2016 AACR癌症研究新视野大会:肿瘤异质性和肿瘤代谢专题介绍以及大会日程

2016-11-01 MedSci MedSci原创

期待已久的第三届AACR癌症研究新视野大会即将于11月2日-5日在上海召开!大会吸引了来自全世界超过400名研究人员,会议期间还将展出组委会专家精选的100多幅学术海报。本次大会由7个专题会议组成,专家们将和大家探讨从实验室研究到临床治疗的整个癌症研究领域的诸多课题。同时,我们还将展示2016年AACR全球年会上发表的重要的癌症科学和医学最新研究成果。  本次大会将围绕“通过癌症科学寻


期待已久的第三届AACR癌症研究新视野大会即将于11月2日-5日在上海召开!大会吸引了来自全世界超过400名研究人员,会议期间还将展出组委会专家精选的100多幅学术海报。本次大会由7个专题会议组成,专家们将和大家探讨从实验室研究到临床治疗的整个癌症研究领域的诸多课题。同时,我们还将展示2016年AACR全球年会上发表的重要的癌症科学和医学最新研究成果。 

本次大会将围绕“通过癌症科学寻找治愈方案”这一主题,重点介绍癌症研究各个重要领域最新和最振奋人心的研究成果,为来自全世界各地的研究人员提供宝贵的交流机会。其中的两个专题,将介绍癌症研究的新领域:肿瘤异质性和肿瘤代谢。我们都知道癌症研究新领域的研究推动着癌症新疗法的诞生和发展。介时会议专题3:“癌症发展和进程的肿瘤异质性”的主持人Luis F. Parada博士及会议专题4:“肿瘤代谢和发展路径”的主持人Bin Tean Teh博士会为大家带来癌症研究新领域的精彩演讲。


北京协和医学院分子肿瘤学国家重点实验室教授王明荣博士将为会议专题3:“癌症发展和进程的肿瘤异质性”作主题为“食管鳞状细胞癌基因组改变的瘤内异质性和克隆演化”开场演讲。Parada博士随后会发表演讲,主题为“源细胞和癌症干细胞对GBM表型的作用”。作为一名发展生物学家,Parada博士是纽约纪念斯隆-凯特琳癌症中心脑肿瘤中心主任。他的实验室使用基因工程小鼠模型研究神经纤维瘤、脑肿瘤、癌症干细胞和肿瘤进展。


在会议专题4:“肿瘤代谢和发展路径”中我们将迎来多位德高望重的科学家与大家分享他们的研究成果,Duojia D. J. Pan博士、Bin Tean Teh博士和Katharine Yen博士。Pan博士是德克萨斯大学西南医学中心生理学系的教授和系主任,他的演讲讲题是“Hippo信号通路对生长控制和其他方面的作用”。Pan博士是Hippo信号通路路径研究方面的开拓者,Hippo信号通路是一种进化式保守发展路径,控制动物的器官尺寸。Teh博士,新加坡国立癌症中心研究室副主任,将发表题为“新陈代谢对癌症恶病质的影响”的演讲。Teh博士的研究重点是亚洲癌症基因组学,在过去的5年里,他在诸多癌症研究方面取得不俗的成果,如胆管癌、膀胱癌和乳腺肿瘤。这个环节的会议最后,Yen博士在带了来题为“癌症IDHm的靶向抑制:AML治疗新方法的开发路线”的演讲。Yen博士是Agios制药公司临床试验部门主任,她带领IDH生物和转化医学研究团队开发了目前临床试验中运用的三种IDH突变体抑制剂:AG-221、AG-120和AG-881。


大会议程











版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707400, encodeId=1c931e074006b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Jan 07 01:32:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196809, encodeId=0acf1968092e, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Fri May 12 00:16:16 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276889, encodeId=b49d12e6889ce, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400352, encodeId=3e071400352ab, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514165, encodeId=53311514165ec, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551977, encodeId=4fec15519e757, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1707400, encodeId=1c931e074006b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Jan 07 01:32:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196809, encodeId=0acf1968092e, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Fri May 12 00:16:16 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276889, encodeId=b49d12e6889ce, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400352, encodeId=3e071400352ab, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514165, encodeId=53311514165ec, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551977, encodeId=4fec15519e757, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=)]
    2017-05-12 laymankey

    感谢分享一下!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1707400, encodeId=1c931e074006b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Jan 07 01:32:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196809, encodeId=0acf1968092e, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Fri May 12 00:16:16 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276889, encodeId=b49d12e6889ce, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400352, encodeId=3e071400352ab, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514165, encodeId=53311514165ec, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551977, encodeId=4fec15519e757, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=)]
    2016-11-03 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1707400, encodeId=1c931e074006b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Jan 07 01:32:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196809, encodeId=0acf1968092e, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Fri May 12 00:16:16 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276889, encodeId=b49d12e6889ce, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400352, encodeId=3e071400352ab, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514165, encodeId=53311514165ec, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551977, encodeId=4fec15519e757, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=)]
    2016-11-03 10518094zz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1707400, encodeId=1c931e074006b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Jan 07 01:32:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196809, encodeId=0acf1968092e, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Fri May 12 00:16:16 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276889, encodeId=b49d12e6889ce, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400352, encodeId=3e071400352ab, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514165, encodeId=53311514165ec, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551977, encodeId=4fec15519e757, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1707400, encodeId=1c931e074006b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Jan 07 01:32:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196809, encodeId=0acf1968092e, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Fri May 12 00:16:16 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276889, encodeId=b49d12e6889ce, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400352, encodeId=3e071400352ab, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514165, encodeId=53311514165ec, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551977, encodeId=4fec15519e757, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Nov 03 05:32:00 CST 2016, time=2016-11-03, status=1, ipAttribution=)]
    2016-11-03 Luyuxie_14

相关资讯

AACR 2015:七大癌症研究热门新技术

在刚刚结束的费城2015年AACR(全美癌症研究者协会)会议上,著名生命科学网站SelectScience公布了“七大癌症研究热门新技术”名单,提名了细胞能量代谢检测、循环肿瘤细胞检测等新技术、新平台。1. 蔡司ZEISS配有Airyscan的 LSM880 获得 Life Science Scientists' Choice 奖项SelectScience宣布蔡司ZEISS配有Airy

AACR 2015:长期规律服用阿司匹林降低结直肠癌患病风险

根据在2015年4月18到22日的AACR年会的研究指出,长期规律服用阿司匹林与结直肠癌整体风险的降低相关。“过去关于阿司匹林与癌症关系的研究在规模大小、随访时间长度或服用阿司匹林与其他的生活方式因素影响方面受到限制。我们的研究提供了关于服用阿司匹林的潜在好处的重要信息,在一个人口众多的群体中研究一系列的剂量、时间和持续使用的时间在其中的影响。”波士顿哈佛公共卫生学院南加利福尼亚长期营养学系的研究

AACR 2015:女性患者福音!Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效

根据2015年4月18到22日举行的AACR年会中的一项Ⅰ期临床试验结果,olaparib (Lynparza)结合卡铂化疗对并没有显著增加女性癌症并患者所经历的副作用,两药的联合治疗则在这些患者中显现出初步临床治疗效应。“PARP(poly ADP-ribose polymerase)抑制剂olaparib最近被FDA批准用于治疗含有一个BRCA突变的卵巢癌女性,” 女性恶性肿瘤学专家、马里兰州

AACR 2016:发布8项重要临床研究更新

2016美国癌症研究协会年会上于4月16 - 20在新奥尔良举行,主题是“通过科学治疗癌症。”

常规注册即将关闭,第三届AACR癌症研究新视野大会不容错失!

常规注册即将关闭,第三届AACR癌症研究新视野大会不容错失!第三届AACR“癌症研究新视野”大会将于2016年11月2-5日在中国上海宝华万豪酒店举行。本次会议主题为“通过癌症科学寻找治愈方案”,其具体议题包括:预防和早期发现、基因组学和表观基因组学、肿瘤异质性、肿瘤代谢、发展路径、免疫治疗、靶向治疗和精准医疗等。大会常规注册通道将于10月21日正式关闭。还未注册的各位同仁,请抓紧时间注册。我们怀